- To produce joint health technology assessments. The joint assessments should be fit for purpose, of high quality, of timely availability, and cover the whole range of health technologies.
- To refine the production processes of joint assessment reports based on lessons learned and experiences from Joint Action 2 and probe a stepped roll-out of additional collaborative assessments yielding timely information.
- To develop and refine a system of horizon scanning, topic selection and prioritisation in close collaboration with the Liaison Committee and relevant Work Packages .
- To develop a process that facilitates the implementation of the joint assessment in the national and regional practice.
- To provide input on final processes and recommendations for a sustainable model of European collaboration on joint assessments after 2020.
Work Package 4 will:
- Produce joint assessments and collaborative assessments:
18 Joint Assessments and 25 Collaborative Assessments on other technologies.
33 Joint Assessments and 4 Collaborative Assessments on pharmaceuticals.
- Deliver a refined production process for joint assessments (relative effectiveness assessments).
- Implement a stepwise work division towards decentralised project management.
- Develop and refine a system for horizon scanning, topic selection and prioritisation of health technologies for relative effectiveness assessments.
- Facilitate the implementation of joint assessments in national/local practice.
- Provide input on recommendations for a sustainable model of European collaboration on joint assessments after 2020.
- Recommendations for horizon scanning, topic selection and prioritization are implemented (in collaboration with Liaison Committee and Work Package 7).
- A process is established for facilitating the implementation of joint assessments in national practice that will be established in a majority of Member States.
- Stakeholder implementation in joint work.
- A framework for the alignment of joint single technology assessments for pharmaceuticals with EMA processes, including early access to data during the assessments of the CHMP that are implemented and structurally used.
- Implement a sustainable production process of European joint assessments as part of a sustainable model for coordination of future European joint assessment collaboration after 2020.
- Determine a sustainable number of joint single technology assessments for pharmaceuticals and joint assessments for other technologies to be completed in Joint Action 3.
- Provide an update on status of the use of additional elements such as conclusions on added therapeutic value and (parts of) cost-effectiveness assessments, in discussion with the Executive Board, could be incorporated in assessment reports. This update may also include a clear description of an adoption process for the joint reports.
AAZ, AETS-ISCIII, AVALIA-T, BIOEF, DEFACTUM (formerly CFK), DPA/MoH Malta, EKAPTY SA, NKUA, EOF, EOPPY, FIMEA, FPS, GOG, HAS, Hdir, HIQA, HIS, HVB, INFARMED, IQWIG, JAZMP, KCE, AIHTA (formerly LBI-HTA), MoH Cyprus, MoH Czech, MoH Slovak Republic, MoH Slovenia, NCPE, NCPHA, NICE, NIJZ, NIPHB, NIPN, NOMA, NSPHMPDB, OCSC, Osteba, RER, SESCS, SU, SUKL, THL, TLV, UBB, UCSC GEMELLI, UMIT, UniBA FOF, UTA, UU, VASPVT, Veneto/CRUF, ZIN